3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
66
Phase 1
26
Phase 1/2
16
Phase 3
15
Phase EARLY_PHASE1
3
Phase 2/3
3
Phase 4
1
Status
Completed
3
Recruiting
2
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Neoplasms
1
Melanoma
1
Interventions
Human Papillomavirus Recombinant Vaccine nonavalent
5
Prednisone
3
Dexamethasone
3
Cisplatin
3
Atorvastatin
3
olaparib
2
lorlatinib
2
human papillomavirus vaccine, L1 type 16, 18
2
enzalutamide
2
adacel
2
Tobacco Use Cessation Devices
2
Tetanus Toxoid
2
Papillomavirus Vaccines
2
Letrozole
2
Diphtheria-Tetanus-acellular Pertussis Vaccines
2
Diphtheria Toxoid
2
Denosumab
2
Carboplatin
2
Anesthesia, Epidural
2
Abiraterone Acetate
2
xiapex
1
venetoclax
1
tirbanibulin
1
tenofovir alafenamide
1
sofosbuvir-velpatasvir drug combination
1
ruxolitinib
1
ribociclib
1
radium Ra 223 dichloride
1
pembrolizumab
1
pasireotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Active not recruiting
×
Ipilimumab
×
Clear all
NCT02068196
2023-03-24
Ipi4
Oslo University Hospital
Phase 4
Active not recruiting
150 enrolled